MONEY20/20
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands.
Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper and Deeploy, alongside executives from the world of cryptocurrency including Kraken and Fireblocks. Nvidia and AWS are back again co-hosting a summit with Money20/20 deep diving into AI.
Scarlett Sieber, Money20/20's Chief Strategy & Growth Officer, emphasised the significance of this year's theme, saying, "I’m delighted to welcome such esteemed powerhouses in the world of finance to what promises to be our biggest and most impactful show in Europe yet. As I will discuss with Former French President François Hollande in our fireside chat, Human X Machine encapsulates the essence of our rapidly evolving financial landscape and underscores the critical intersection of human ingenuity and artificial intelligence in shaping our financial future. The power of the Money20/20 platform is that the collective ecosystem of money at the most senior level comes together to have active discussions on the most important topics, breaking news, and work together to pave the way for a more resilient and inclusive financial ecosystem.”
Pav Gill, the Wirecard whistleblower, and one of Money20/20 Europe’s keynote speakers said, "Speaking at Money20/20 Europe is more than an opportunity; it's a reflection of a journey that took me from the heart of the Wirecard scandal to the helm of Confide. Unveiling one of finance's largest deceptions wasn't just about exposing truths; it was about sparking change. At Confide, we're building the future of business integrity, using technology to ensure that the lessons learned from Wirecard and the many other scandals pave the way for a more accountable and transparent industry. I look forward to sharing this mission and inspiring action towards a culture where ethics and technology intersect to create safer business environments for all.”
Sessions at Money20/20 Europe will revolve around five key topic areas within the show’s Human X Machine theme. They are as follows:
- A Customer Universe of One: Finance is becoming a Universe of One; A place where hyper-personalisation occurs at a microscopic level across every touchpoint.
- The Age of Atomic Finance: The Universe of One is made possible by monumental technological advancements, from artificial intelligence and cryptography to quantum computing. These leaps in technology have delivered atomic-level precision, unlocking the potential for a Universe of One.
- Meet the Architects: From the leaders of trailblazing startups to changemakers in agile incumbents, we’ll showcase the architects of the new dawn; the visionaries who create new landscapes for our financial futures.
- Signal Vs Noise: The pace of financial innovation continues accelerating, fueled by emerging technologies like AI, blockchain, and Web3. Yet visionary breakthroughs live alongside hype-driven tangents. We need voices committed to elevating discourse and realising technology’s potential through innovation geared towards progress.
- The Business of Money: Hear from founders, key decision makers, consultants, investors, and disruptors. We’ll delve into the actions that led to success, and just as crucially we’ll carry out an audit on the activities that produced undesirable outcomes.
The Money20/20 Europe agenda can be found here, while the lineup of confirmed speakers can be found here.
Media who would like to attend Money20/20 Europe can register for a complimentary press pass here.
About Money20/20
Launched by industry insiders in 2012, Money20/20 has rapidly become the heartbeat of the global fintech ecosystem. Over the last decade, the most innovative, fast-moving ideas and companies have driven their growth on our platform. Mastercard, Airwallex, J.P. Morgan, SHIELD, GCash, Stripe, Google, Marqeta, VISA, Adyen, Checkout.com and more make transformational deals and raise their global profile with us. Money20/20 attracts leaders from the world’s greatest VC firms, banks, regulators and media platforms: convening to cut industry-shaping deals, build world-changing partnerships and unlock future-defining opportunities in Bangkok (23-25 April 2024), Amsterdam (4-6 June 2024) and Las Vegas (27-30 October 2024). Money20/20 also recently launched Twentyfold, a Digital Intelligence product containing the deepest and widest repository of fintech startup data in the world. Money20/20 is where the world’s fintech leaders convene to grow their businesses. Money20/20 is part of Ascential plc. Follow Money20/20 on X and LinkedIn for show developments and updates. We’re Where Money Does Business.
Follow Money20/20 on Twitter for show developments and updates.
You can also find us on LinkedIn at Money20/20.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416620432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom